Fully-integrated, component-based CDMS offers flexibility, customization, and efficiency.
There's no one-size-fits-all approach during the COVID-19 pandemic
Lessons from six months of conducting clinical trials during the COVID-19 pandemic
Recent study results highlight need for new metrics in ECOG scoring to mitigate variability.
Regulations that apply across geographic borders can provide researchers and patients a firmer foundation on data protection.
As clinical research continues to globalize and grow at pace, there is a risk that global greenhouse gas emissions will escalate unless mitigation strategies are actively included in corporate strategies.
COVID-19 forces life sciences industry to make long overdue changes.
Teams must work together with technology solutions and optimize integration to unlock their full potential.
Wearable sensors and remote monitoring technology can help HCPs monitor and manage COPD more effectively.
Bayesian methods bring flexibility and speed to clinical trial design and analysis, and with increased access to the necessary computational power, are transforming today’s clinical research.
Concept of flexibility acting as driving force behind industry’s swift response to COVID-19.
How cognitive evaluations can aid in meeting the growing demand for more comprehensive safety profiles.
Three key considerations for deploying technology to help increase diversity in trials.
Optimizing feasibility through increased data collection.
Trials that address multiple questions simultaneously using a master protocol can be operationally complicated. These complexities can be managed, even in studies used to support a marketing application.
Key takeaways from a survey of 250 oncology patients measuring COVID-19’s impact on patient willingness to participate in clinical trials.
Distinguishing CAR-T and CPI approaches and the clinical trial challenges and complexities associated with each.
This eBook will discuss three key ways that researchers can implement AI to address data challenges, improve patient safety and outcomes, and accelerate processes.
With close collaboration between sponsors, CROs, and regulators, this emerging technology has the potential to greatly improve the lives of patients.
2020 Tufts CSDD study examines relationship between investigative site personnel diversity and study participant diversity.
Alleviating sponsor and investigator concerns around sharing of remote-assessment data in accordance with GCP and GDPR standards.
Eliminating barriers to engage underrepresented populations.
By integrating real-world data more deeply into the process of clinical research, life sciences stakeholders can open up new possibilities for therapeutic development and the evidence-based treatment of hematologic cancers.
Reliable internet connection an integral part of movement to DCTs.
Unlocking the full potential of artificial intelligence requires these stakeholders to ensure their data are accessible and secure.
A top 5 sponsor turned to WCG to recruit expecting mothers for its Phase III RSV vaccine trial. WCG support covered multiple countries and contributed almost one third of overall randomizations in the supported countries, bringing the study in ahead of schedule despite delays due to COVID-19 impacts on RSV seasonality. The sponsor met study timeline past enrollment by continuing to work with WCG’s retention support.
A look at the future of clinical trial laboratory testing amid the emerging use of new devices at the point of care.
It takes a village to raise a trial, but most stakeholders are siloed on isolated islands.